4-hydroxy-3-(4-nitrobenzoylamino)phenylacetic acid methyl ester | 695187-47-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-hydroxy-3-(4-nitrobenzoylamino)phenylacetic acid methyl ester
• 英文别名: Methyl 2-[4-hydroxy-3-[(4-nitrobenzoyl)amino]phenyl]acetate
• CAS: 695187-47-4
• 化学式: C₁₆H₁₄N₂O₆
• 分子量: 330.297
• InChiKey: FRKHSIYDJFVBLI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  121
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-hydroxy-3-(4-nitrobenzoylamino)phenylacetic acid methyl ester 在 对甲苯磺酸 、 溶剂黄146 、 锌 作用下， 以 乙醇 、 甲苯 为溶剂， 生成 methyl 2-(2-(4-aminophenyl)benzo[d]oxazol-5-yl)acetate
  参考文献：
  名称：

  Furanyl-1,3-thiazol-2-yl and benzoxazol-5-yl acetic acid derivatives: novel classes of heparanase inhibitor

  摘要：

  Using a furanylthiazole acetic acid as a starting point, a novel series of benzoxazol-5-yl acetic acid derivatives have been identified as heparanase inhibitors. Several compounds possess an IC50 of similar to 200 nM against heparanase, for example, trans 2-[4-[3-(3,4-dichlorophenylamino)-3-oxo-1-propenyl]-2-fluorophenyl]benzoxazol-5-yl acetic acid (16e). Several of the compounds show anti-angiogenic properties. Improvement to the DMPK profile of compounds has provided compounds of potential use in in vivo models. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.014
• 作为产物：
  描述：

  4-羟基-3-硝基苯乙酸 在 palladium on activated charcoal 盐酸 、 氢气 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 生成 4-hydroxy-3-(4-nitrobenzoylamino)phenylacetic acid methyl ester
  参考文献：
  名称：

  Furanyl-1,3-thiazol-2-yl and benzoxazol-5-yl acetic acid derivatives: novel classes of heparanase inhibitor

  摘要：

  Using a furanylthiazole acetic acid as a starting point, a novel series of benzoxazol-5-yl acetic acid derivatives have been identified as heparanase inhibitors. Several compounds possess an IC50 of similar to 200 nM against heparanase, for example, trans 2-[4-[3-(3,4-dichlorophenylamino)-3-oxo-1-propenyl]-2-fluorophenyl]benzoxazol-5-yl acetic acid (16e). Several of the compounds show anti-angiogenic properties. Improvement to the DMPK profile of compounds has provided compounds of potential use in in vivo models. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.014

文献信息

• Novel Symmetrical Benzazolyl Derivatives Endowed with Potent Anti-Heparanase Activity
  作者：Antonella Messore、Valentina Noemi Madia、Luca Pescatori、Francesco Saccoliti、Valeria Tudino、Alessandro De Leo、Martina Bortolami、Daniela De Vita、Luigi Scipione、Federico Pepi、Roberta Costi、Silvia Rivara、Laura Scalvini、Marco Mor、Fabiana Fosca Ferrara、Emiliano Pavoni、Giuseppe Roscilli、Giuliana Cassinelli、Ferdinando M. Milazzo、Gianfranco Battistuzzi、Roberto Di Santo、Giuseppe Giannini

  DOI：10.1021/acs.jmedchem.8b01497

  日期：2018.12.13

  Previously, we explored 2-(4-(4-(bromo-methoxybenzamido)benzylamino)phenyl) benzazole derivatives as anti-heparanase agents, proposing this scaffold for development of broadly effective heparanase inhibitors. Herein, we report an extended investigation of new symmetrical 2-aminophenyl-benzazolyl-5-acetate derivatives, proving that symmetrical compounds are more effective than asymmetrical analogues,

  乙酰肝素酶是唯一的哺乳动物内毒素-β- d-葡糖醛酸糖苷酶涉及多种主要疾病。乙酰肝素酶表达的上调增加了肿瘤的大小，血管生成和转移，代表了在抗癌领域中已被验证的靶标。迄今为止，仅描述了几种小分子抑制剂，但尚未通过临床前开发获得。以前，我们探索了2-（4-（4-（溴-甲氧基苯甲酰胺基）苄氨基）苯基）苯并唑衍生物作为抗乙酰肝素酶的药物，建议将该支架用于开发广泛有效的乙酰肝素酶抑制剂。本文中，我们报告了对新的对称的2-氨基苯基-苯并甲氮基-5-乙酸酯衍生物的扩展研究，证明了对称化合物比不对称类似物更有效，其中最有效的化合物为7g，在纳摩尔浓度下对乙酰肝素酶有活性。对作用最佳的化合物5c和7g进行了分子对接研究，以使它们与酶的相互作用合理化。此外，侵袭分析证实了化合物5c，7a和7g的抗转移潜力，证明抑制了肿瘤细胞中促血管生成因子的表达。
• [EN] BENZOXAZOLE, BENZTHIAZOLE AND BENZIMIDAZOLE ACID DERIVATIVES AND THEIR USE AS HEPARANASE INHIBITORS<br/>[FR] DERIVES D'ACIDES DE BENZOXAZOLE, DE BENZOTHIAZOLE, ET DE BENZIMIDAZOLE PHARMACEUTIQUEMENT ACTIFS
  申请人：OXFORD GLYCOSCIENCES UK LTD

  公开号：WO2004046122A2

  公开（公告）日：2004-06-03

  Compounds of formula (I): wherein R1, R2 and R3 are independently, hydrogen, halogen, CF3, OR6, NR7R8, NR8COR10, NR8SO2R10 or C1-6 alkyl optionally substituted by hydroxy, C1-6 alkoxy or NR7R8; R4 is NR8CONR8R9, NR8COR9, NR8SO2R9, or W-CONR8R9, where W is a bond, C1-6 alkylene, C2-6 alkenylene or C2-6 alkynylene; and R5 is Formula (A) methods for their synthesis, pharmaceutical compositions comprising them and their use in medicine, in particular for the treatment of cancer.
• Furanyl-1,3-thiazol-2-yl and benzoxazol-5-yl acetic acid derivatives: novel classes of heparanase inhibitor
  作者：Stephen M. Courtney、Philip A. Hay、Richard T. Buck、Claire S. Colville、David J. Phillips、David I.C. Scopes、Faye C. Pollard、Martin J. Page、James M. Bennett、Margaret L. Hircock、Edward A. McKenzie、Maina Bhaman、Robert Felix、Colin R. Stubberfield、Paul R. Turner

  DOI：10.1016/j.bmcl.2005.03.014

  日期：2005.5

  Using a furanylthiazole acetic acid as a starting point, a novel series of benzoxazol-5-yl acetic acid derivatives have been identified as heparanase inhibitors. Several compounds possess an IC50 of similar to 200 nM against heparanase, for example, trans 2-[4-[3-(3,4-dichlorophenylamino)-3-oxo-1-propenyl]-2-fluorophenyl]benzoxazol-5-yl acetic acid (16e). Several of the compounds show anti-angiogenic properties. Improvement to the DMPK profile of compounds has provided compounds of potential use in in vivo models. (c) 2005 Elsevier Ltd. All rights reserved.